Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that topical cetirizine 1% may be effective in treating androgenetic alopecia in men, with some patients experiencing new hair growth compared to none in the placebo group.

In this study, a novel AR protein degrader was shown to reverse DHT-induced hair regrowth delay in a mouse model of androgenetic alopecia, with minimal circulation and potential side effects.

This study concluded that psychological well-being and self-image among Filipino males with androgenetic alopecia may be influenced by age, education level, and disease severity.

This study found that Ageratum conyzoides showed antihyperglycemic and antilipidemic effects in diabetic rats, with significant changes in hematological and serum electrolyte parameters at 2000mg/kg.

This study found that breast cancer patients treated with the docetaxel-doxorubicin regimen experienced various adverse drug reactions, with nausea being the most common and mainly mild in severity.

This study revealed that Thai youths who are more worried about androgenetic alopecia tend to experience higher severity of the condition, poorer quality of life, and increased use of multiple hair styling products.

This study found that the ACE gene I/D polymorphism may serve as a genetic susceptibility indicator for androgenetic alopecia in an Egyptian patient group.

This study found that N-acetyl-GED may protect and partially rescue human hair follicles from experimentally-induced epithelial-mesenchymal transition ex vivo, suggesting its potential in treating scarring alopecias like lichen planopilaris.

This study found that AIRE, a usually nuclear protein, is expressed in the cytoplasm of human epidermal and follicular keratinocytes and associates with the intermediate filament protein cytokeratin 17, potentially impacting ectodermal abnormalities in APECED syndrome.

This study found that a novel dietary supplement, AGA-P, when combined with minoxidil and finasteride, significantly improved the clinical efficacy of these drugs for treating mild-to-severe androgenic alopecia compared to drug treatment alone over six months.

This study found that college students with androgenetic alopecia exhibited higher levels of various psychological symptoms compared to those without AGA, with medical and art students showing particularly elevated symptoms.

This study found that cepharanthine can inhibit gastric cancer cell activity by inducing oxidative stress and altering energy metabolism, suggesting its potential for gastric cancer treatment.

In a testosterone-induced mouse model of androgenetic alopecia, this study found that oral and topical administration of Connarus semidecandrus Jack ethanol extract promoted hair regrowth and improved hair health markers similar to finasteride, without detectable liver or kidney toxicity.

This study found that a novel treatment for androgenetic alopecia in Korean individuals effectively reduced the affected areas and provided satisfactory outcomes for both male and female participants.

In this study, cetirizine hydrochloride was formulated into niosomal and cubosomal gels, showing potential for off-label use in treating androgenic alopecia due to effective skin permeation and acceptable safety profiles; cubosomal gels exhibited superior permeation compared to niosomal gels.

This study found that high skin expression of amphiregulin in acute graft-versus-host disease was associated with severe disease grade, poor overall survival, and increased non-relapse mortality.

This review discusses treatments for androgenic alopecia, including minoxidil, finasteride, and hormonal therapies with antiandrogens, and reports no new clinical findings.

In this retrospective study conducted at a trichology clinic, the off-label use of upadacitinib for at least 24 weeks was found to have a promising efficacy and safety profile for treating severe alopecia areata in adolescents.

This review discusses recent research on the use of concentrated growth factor (CGF) for treating androgenetic alopecia, highlighting its potential to enhance hair regrowth and improve hair density but noting the need for high-quality clinical trials.

In this case series, researchers reported an unexpectedly rapid and positive response to a topical, hydrogel-based botanical treatment for androgenetic alopecia in both male and female volunteers, achieving significant improvement in hair loss within 90 days instead of the planned 270 days.

This dataset provides supplemental material for a study on long-term particulate matter exposure and androgenetic alopecia risk, including additional exposure data and sensitivity analyses, but reports no new clinical results.

This case report describes the first known instance of hair loss linked to agomelatine, which resolved after the drug was discontinued.

This literature review found that androgenetic alopecia has a complex multifactorial etiology and effective management should be tailored to individual severity and gender to improve patients' quality of life.

This review concluded that while topical prostaglandin analogues show some potential in treating androgenetic alopecia, evidence is still limited and no products have regulatory approval.

This study examined the current prescribing patterns of Australian dermatologists in treating androgenetic alopecia in men, highlighting the limited treatment options available despite the condition's prevalence and psychological impact.

Androgenetic alopecia (AGA) is a common, hereditary hair loss condition that can be slowed but not permanently reversed with available therapies.

This review discusses the increased prevalence of androgenic alopecia in men and women, highlighting the limited FDA-approved treatment options, and reports no clinical results; the authors note adherence challenges due to prolonged drug use.

This study reports that combination therapies, including surgical and various medical treatments, show promise for managing androgenetic alopecia, though further research is necessary to confirm the safety and effectiveness of emerging therapies.

This study found that the PPAR-γ modulator AGED can reverse epithelial-mesenchymal transition in hair follicles affected by lichen planopilaris ex vivo, suggesting potential for treating scarring alopecias.

This study reports that Korean adolescents with androgenetic alopecia tend to have milder symptoms than adults and a higher prevalence of family history of alopecia.